Kozycki et al.3 noted that ROSAH patients frequently present with elevated plasma IL-6 levels and that tocilizumab improved intraocular inflammation (two of two patients) while also positively impacting other parameters after treatment initiation3. Here, IL6 is linked to retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome.